 Home > Active Ingredient News > Study of Nervous System > Mov Disord: neurofilament light chain, can predict cognitive decline in patients with Parkinson's

Mov Disord: neurofilament light chain, can predict cognitive decline in patients with Parkinson's

 Last Update: 2021-09-29
 Source: Internet
 Author: User

Tags

alzheimer's biomarkers

bench scale

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Throughout neurodegenerative diseases, biomarkers can improve the accuracy of diagnosis , help prognosis, and provide information for clinical trial design
.

Although biomarkers are routinely used for Alzheimer's disease (AD), the development of biomarkers has proven to be more challenging in Parkinson's disease (PD)

diagnosis

Unlike amyloid-β and tau in AD, no radioligand can be used to detect the hallmark pathological protein of Parkinson's disease--α-ynuclein, while the level of α-ynuclein in cerebrospinal fluid (CSF) is in patients and controls There is overlap between
.

So far, no specific blood or CSF biomarkers have been used for the clinical diagnosis or management of PD
.

manage

In recent years, neurofilament light chain protein (NfL) has become a promising biomarker in a variety of neurodegenerative diseases
.

NfL is a neuron-specific component of the axon cytoskeleton, which can enter the extracellular space after axon damage or death; NfL has been quantified in plasma, serum and CSF

Although relatively non-specific, the NfL values in these intervals can be used as candidate biomarkers for nerve axon damage

However, few large-scale studies have performed longitudinal analysis of plasma and cerebrospinal fluid NfL
.

No previous studies have explored the question of whether plasma NfL levels at a single time point can predict longitudinal clinical outcomes
.

Using a large single-center cohort, Whitley W.

They included 615 participants with neurodegenerative diseases, including 152 PD and 200 healthy control participants, and provided plasma and/or cerebrospinal fluid (CSF) NfL samples
.

The Kruskal-Wallis grade test was used to compare the diagnostic groups

They found that there is a great correlation between plasma and cerebrospinal fluid NfL levels (Spearman r = 0.

64, P <0.
001); NfL is the highest in neurocognitive disorders

In general, plasma NfL is a useful prognostic biomarker of PD, which can predict clinical conversion to mild cognitive impairment or dementia
.

Original source:
Aamodt WW, Waligorska T, Shen J, et al.

Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease .
Mov Disord.
Published online September 4, 2021:mds.
28779.
doi:10.
1002/mds.
28779

Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.